Mississauga, ON -- (SBWire) -- 05/22/2015 --AllPennyStocks.com Media, Inc. (http://www.AllPennyStocks.com/) announces its latest article titled "Cellceutix Gets Nod From IRB For Additional Enrollment in Clinical Trial of New Cancer Drug Candidate."
Companies mentioned in this article include Cellceutix Corporation (OTCPK:CTIX).
Article Excerpt:
A recent report showed that worldwide spending on cancer drugs has hit $100 billion for the first time. Spending on oncology drugs has increased to record levels even as several innovative treatments are still under development.
The IMS Institute for Healthcare Informatics reported recently that worldwide spending on cancer drugs reached $100 billion, increasing 10% from the previous year. One reason why spending on cancer drugs has reached such levels is because many drugs are priced at well over $100,000. In fact, prices of several cancer drugs that are currently in development are expected to be even higher.
Among the cancer therapies currently under development, the one that has created the most excitement is immunotherapy, which harnesses the body's immune system to fight tumors. Several major pharma companies are developing their own immunotherapies and it is one of the hottest areas in cancer research.
The full version of this article can be found at:
http://www.allpennystocks.com/aps_us/special-reports/536/cellceutix-gets-nod-from-irb-for-additional-enrollment-in-clinical-trial-of-new-cancer-drug-candidate.htm
About AllPennyStocks.com
AllPennyStocks.com is focused on the small-cap / penny stock market and has become a reputable name in the investment community. AllPennyStocks.com runs a Canadian and US site to provide investors in Canada as well as the United States with informative and unique content and information. AllPennyStocks.com runs daily technical penny stocks to watch, has a daily market write-up, provides company spotlights, runs unique most active pages strictly for penny stocks trading on the TSX, TSX Venture, NASDAQ and OTC BB, and much more information for the average investor.
AllPennyStocks.com also runs an email newsletter that aims to uncover stocks that are still under the radar of most investors. Criteria AllPennyStocks.com looks for includes strong revenues, a seasoned management, innovative business plans, among many others. AllPennyStocks.com also looks for companies that announce breaking news, recent 52-week highs/lows, technical breakouts, and other favorable corporate information.
Investors are encouraged to subscribe to the AllPennyStocks.com FREE e-mail newsletter and see what tens of thousands of other investors have already been receiving since 1999. Investors can receive their free newsletter subscription by clicking here: http://www.allpennystocks.com/aps_common/newsletter_free.asp.
Contact:
AllPennyStocks.com Media, Inc.
Peter Szafranski -- President
Phone: (905) 361-5680
E-Mail: peter@allpennystocks.com
Websites: http://www.allpennystocks.com / http://www.bullishinvestor.com
Note: AllPennyStocks.com has not received compensation for carrying the above-mentioned company; a full disclaimer can be viewed here: http://www.allpennystocks.com/aps_common/disclaimer.asp.
All Penny Stocks.com News: Cellceutix Gets Nod from IRB for Additional Enrollment in Clinical Trial of New Cancer Drug Candidate